FLUOXETINE HYDROCHLORIDE

Details

Stereochemistry	RACEMIC
Molecular Formula	C17H18F3NO.ClH
Molecular Weight	345.787
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C2=CC=CC=C2

InChI

InChIKey=GIYXAJPCNFJEHY-UHFFFAOYSA-N

InChI=1S/C17H18F3NO.ClH/c1-21-12-11-16(13-5-3-2-4-6-13)22-15-9-7-14(8-10-15)17(18,19)20;/h2-10,16,21H,11-12H2,1H3;1H

HIDE SMILES / InChI

Molecular Formula	C17H18F3NO
Molecular Weight	309.3261
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf | https://www.drugs.com/fluoxetine.html

Fluoxetine hydrochloride is the first agent of the class of antidepressants known as selective serotonin-reuptake inhibitors (SSRIs). Fluoxetine is a racemic mixture of the R- and S- enantiomers and are of equivalent pharmacologic activity. Despite distinct structural differences between compounds in this class, SSRIs possess similar pharmacological activity. As with other antidepressant agents, several weeks of therapy may be required before a clinical effect is seen. SSRIs are potent inhibitors of neuronal serotonin reuptake. They have little to no effect on norepinephrine or dopamine reuptake and do not antagonize α- or β-adrenergic, dopamine D2 or histamine H1 receptors. During acute use, SSRIs block serotonin reuptake and increase serotonin stimulation of somatodendritic 5-HT1A and terminal autoreceptors. Fluoxetine is marketed under the trade names Prozac and Sarafem among others. It is also marketed for the treatment of premenstrual dysphoric disorder (Sarafem®, fluoxetine hydrochloride). PROZAC is a selective serotonin reuptake inhibitor indicated for: • Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years • Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years • Acute and maintenance treatment of Bulimia Nervosa in adult patients • Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients. Studies at clinically relevant doses in man have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine. Antagonism of muscarinic, histaminergic, and α1-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Serotonin transporter 172 Target ID: CHEMBL228 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/9537821 \| https://www.ncbi.nlm.nih.gov/pubmed/19329313 \| https://www.ncbi.nlm.nih.gov/pubmed/17910821	Inhibitor 8146		10.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Major depressive disorder 172 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8307	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Obsessive-compulsive disorder 28 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8307	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Bulimia nervosa 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8307	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11
Panic disorder 22 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	Primary	Approved 8307	PROZAC Approved Use Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years (1.1) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years (1.2) Acute and maintenance treatment of Bulimia Nervosa in adult patients (1.3) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients (1.4) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults (1.5) 1.1 Major Depressive Disorder Fluoxetine hydrochloride is indicated for the acute and maintenance treatment of Major Depressive Disorder in adult patients and in pediatric patients aged 8 to18 years [see CLINICAL STUDIES (14.1) Launch Date 5.6773437E11

C_max

Value	Dose	Co-administered	Analyte	Population
22.56 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
13576.38 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1101.46 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
788626.72 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
46.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/15968712	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED
49.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/16229112	20 mg single, oral dose: 20 mg route of administration: Oral experiment type: SINGLE co-administered:		FLUOXETINE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
5.5% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf			FLUOXETINE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1532 substrate 1670	inhibitor 1695 substrate 985	inhibitor 1789 substrate 1168	inhibitor 1570

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
Cav3.1 7 Cav3.2 12 Cav3.3 7 P-gp 1401 CYP2C19 1410 OCT1 498 OCT2 630	P-gp 1491 CYP1A2 1013 CYP2B6 648 CYP2C19 955 CYP3A5 383	BCRP 74

Drug as perpetrator

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/ \| https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	moderate [IC50 31 uM]
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11876575/	moderate	norfluoxetine 2
P-gp 1588	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12649369/	moderate	norfluoxetine 2
CYP3A4 1857	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/	moderate		yes (co-administration study) Comment: addition of fluoxetine 20 mg/day to pre-existing risperidone therapy produced a mean 4- fold increase in plasma risperidone concentration, with some patients exhibiting an increase as large as 10-fold Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/
BCRP 751	inducer 1515 Sources: https://pubmed.ncbi.nlm.nih.gov/31037729/	no
CYP2D6 1826	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf	strong [IC50 1.05 uM]		yes (co-administration study) Comment: Coadministration of fluoxetine with other drugs that are metabolized by CYP2D6, including certain antidepressants (e.g., TCAs), antipsychotics (e.g., phenothiazines and most atypicals), and antiarrhythmics (e.g., propafenone, flecainide, and others) should be approached with caution Sources: https://pubmed.ncbi.nlm.nih.gov/12172343/ \| https://pubmed.ncbi.nlm.nih.gov/27188854/ \| https://pubmed.ncbi.nlm.nih.gov/11876575/ \| https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf
Cav3.1 7	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 14 uM]
Cav3.2 12	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 16 uM]
OCT2 631	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 3.32 uM]
Cav3.3 7	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 30 uM]
Cav3.3 7	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/16510561/	yes [IC50 5 uM]	norfluoxetine 2
OCT1 513	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/24688079/ \| https://pubmed.ncbi.nlm.nih.gov/30361780/	yes [IC50 6.2 uM]
CYP2C9 1747	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/9384467/	yes
CYP2C19 1484	inhibitor 3185 Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/	yes		yes (co-administration study) Comment: Fluoxetine dosing inhibited CYP2C19 activity in both age groups, increasing the (S)- to (R)-mephenytoin ratio 3- to 4-fold Sources: https://pubmed.ncbi.nlm.nih.gov/11270912/

Drug as victim

Target	Modality	Activity
P-gp 1491	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/21718296/ \| https://pubmed.ncbi.nlm.nih.gov/17962372/	minor
CYP2C9 985	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/\| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes [Ki 19 uM]
CYP1A2 1013	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2B6 648	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2C19 955	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP2D6 1168	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/ \| https://pubmed.ncbi.nlm.nih.gov/16472103/ \| https://pubmed.ncbi.nlm.nih.gov/24464553/	yes
CYP3A4 1670	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes
CYP3A5 383	substrate 3264 Sources: https://pubmed.ncbi.nlm.nih.gov/10997938/	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/ \| https://pubmed.ncbi.nlm.nih.gov/11805215/
hERG 1603	inhibitor 1584 Sources: https://pubmed.ncbi.nlm.nih.gov/16967046/		norfluoxetine 2

Sourcing

Vendor/Aggregator	ID	URL
3B Scientific (Wuhan) Corp	3B3-034390	http://www.3bsc.com/index/pro_info.php?id=56297
AA Blocks	AA00I9Q5	http://www.aablocks.com/goods/Goods/detail?id=AA00I9Q5
AHH Chemical co.,ltd	MT-51855	http://www.ahhchemical.com/product/MT-51855.html
Aaron Chemicals	AR00IAHX	http://www.aaronchem.com/54910-89-3
Acadechem	ACDC-070879	http://acadechemical.com/product/11474
Achemo Scientific Limited	AC-14816	http://www.achemo.com/product_view.asp?ID=4706
Achemtek	0104-002971	http://www.achemtek.com/54910-89-3
Alfa Chemistry	54910-89-3	https://www.alfa-chemistry.com/fluoxetine-cas-54910-89-3-item-292572.htm
Alinda	ALBB-025606	http://alinda.ru/finechem_en_.html?i=ALBB-025606
ApexBio Technology	A2436	http://www.apexbt.com/fluoxetine-hcl.html
AvaChem Scientific	2877B	http://www.avachem.com/productSearch.asp?2877B
BLD Pharm	BD130609	http://www.bldpharm.com/products/54910-89-3.html
BOC Sciences	1173147-79-9	https://www.bocsci.com/fluoxetine-d5-solution-cas-1173147-79-9-item-185463.html
BioChemPartner	BCP28440	http://www.biochempartner.com/54910-89-3-BCP28440
Chem Scene	CS-2861	http://www.chemscene.com/54910-89-3.html
ChemMol	30103987	http://www.chemmol.com/chemmol/30103987.html
ChemMol	49402399	http://www.chemmol.com/chemmol/49402399.html
Chemenu	CM118045	http://www.chemenu.com/products/CM118045
Chemspace	CSSB00000726877	https://chem-space.com/CSSB00000726877
Clearsynth	CS-O-01527	http://www.clearsynth.com/en/CSO01527.html
Debye Scientific	DB-015148	http://www.debyesci.com/cas_54910-89-3.html
Finetech	FT-0626489	http://www.finetechnology-ind.com/prod/detail/pub/54910-89-3.html
Glentham Life Sciences	GP3875	http://www.glentham.com/products/product/GP3875/
Lab Network	LN00287054	https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00287054
MedChem Express	HY-B0102	https://www.medchemexpress.com/fluoxetine.html
MuseChem	I004030	https://www.musechem.com/product/I004030.html
Smolecule	S590536	https://www.smolecule.com/products/s590536
THE BioTek	bt-305245	https://www.thebiotek.com/product/others/bt-305245
Yuhao Chemical	LT4939	http://www.chemyuhao.com/54910-89-3.html
abcr GmbH	AB377357	http://www.abcr.com/shop/en/AB377357
iChemical	EBD34153	http://www.ichemical.com/products/54910-89-3.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs

PubMed

Title	Date	PubMed
Urinary retention with reboxetine-fluoxetine combination in a young man.	2000 Dec	11190365
Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.	2000 Dec 5	11104741
Fluoxetine-induced sexual dysfunction reversed by trazodone.	2000 Nov	11143841
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.	2000 Oct	11078032
Fluoxetine toxicity in a preterm infant.	2000 Oct-Nov	11076330
Evidence of early onset of antidepressant effect in randomized controlled trials.	2001	11229783
Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.	2001	11229449
Dopaminergic activity in transgenic mice underexpressing glucocorticoid receptors: effect of antidepressants.	2001	11226678
Fluoxetine: a review of its therapeutic potential in the treatment of depression associated with physical illness.	2001	11217873
Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain.	2001	11077072
Effects of selective serotonin reuptake inhibitors on sexual function.	2001 Apr	11270925
Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.	2001 Apr	11270917
Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin.	2001 Apr	11270913
Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers.	2001 Apr	11270912
Serotonergic manipulations both potentiate and reduce brain stimulation reward in rats: involvement of serotonin-1A receptors.	2001 Apr	11259559
Idazoxan and 8-OH-DPAT modify the behavioral effects induced by either NA, or 5-HT, or dual NA/5-HT reuptake inhibition in the rat forced swimming test.	2001 Apr	11182533
Social impulsivity inversely associated with CSF 5-HIAA and fluoxetine exposure in vervet monkeys.	2001 Apr	11182532
Effect of chronic and acute administration of fluoxetine and its additive effect with morphine on the behavioural response in the formalin test in rats.	2001 Feb	11273019
Characterization of 5-HT receptors in the parasitic nematode, Ascaris suum.	2001 Feb	11272652
Subjective and discriminative stimulus effects of two de-nicotinized cigarettes with different tar yields.	2001 Feb	11260814
Rapid desensitization of 5-HT(1A) receptors in Fawn-Hooded rats after chronic fluoxetine treatment.	2001 Feb	11226808
Severe symptomatic hyponatremia during citalopram therapy.	2001 Feb	11217819
Influence of coadministration of fluoxetine on cisapride pharmacokinetics and QTc intervals in healthy volunteers.	2001 Feb	11213850
Reversible galactorrhea and prolactin elevation related to fluoxetine use.	2001 Feb	11213313
Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers.	2001 Feb	11210405
Dose-dependent seizure activity associated with fluoxetine therapy.	2001 Feb	11181988
Acute hypokalemic paralysis associated with long-term lithium therapy.	2001 Feb	11180215
Fluoxetine and side effects in the geriatric population.	2001 Feb 1	11272295
Adhyperforin as a contributor to the effect of Hypericum perforatum L. in biochemical models of antidepressant activity.	2001 Feb 23	11263672
Fluoxetine (Prozac) as a cause of QT prolongation.	2001 Feb 26	11252125
Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients.	2001 Jan	11225566
Treatment of bipolar depression with twice-weekly fluoxetine: management of antidepressant-induced mania.	2001 Jan	11197585
Fluoxetine-induced Ca2+ signals in Madin-Darby canine kidney cells.	2001 Jan	11191831
Central 5-hydroxytryptamine-2A receptor expression in transgenic mice bearing a glucocorticoid receptor antisense.	2001 Jan	11174015
Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats.	2001 Jan	11151029
Atrial arrhythmia in a woman treated with fluoxetine: is there a causal relationship?	2001 Jan	11145788
A novel augmentation strategy for treating resistant major depression.	2001 Jan	11136647
Depression among pregnant adolescents: an integrated treatment approach.	2001 Jan	11136628
Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal.	2001 Jan	11106878
Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635.	2001 Jan	11106871
Fluoxetine in the treatment of Huntington's disease.	2001 Jan 1	11205429
Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment: a positron emission tomography provocation study.	2001 Jan 12	11121880
No gender differences in placebo responses of patients with major depressive disorder.	2001 Jan 15	11164762
Fluoxetine (Sarafem) for premenstrual dysphoric disorder.	2001 Jan 22	11177220
Plasticity in serotonin uptake in primary neuronal cultures of serotonin transporter knockout mice.	2001 Jan 31	11172895
Regulation of the vesicular monoamine transporter-2: a novel mechanism for cocaine and other psychostimulants.	2001 Mar	11181904
Addition of a 5-HT receptor agonist to methylphenidate potentiates the reduction of [123I]FP-CIT binding to dopamine transporters in rat frontal cortex and hippocampus.	2001 Mar 1	11169768
Modafinil does not affect serotonin efflux from rat frontal cortex synaptosomes: comparison with known serotonergic drugs.	2001 Mar 16	11251206
Repeated electroconvulsive stimulation, but not antidepressant drugs, induces mossy fibre sprouting in the rat hippocampus.	2001 Mar 2	11222992
Adding group psychotherapy to medication treatment in dysthymia: a randomized prospective pilot study.	2001 Spring	11264333

Patents

Sample Use Guides

In Vivo Use Guide

Usual Adult Dose for Bulimia Immediate-release oral formulations: Recommended dose: 60 mg orally once a day Usual Adult Dose for Depression Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Delayed release oral capsules: Initial dose: 90 mg orally once a week, commenced 7 days after the last daily dose of immediate-release fluoxetine 20 mg formulations. Usual Adult Dose for Obsessive Compulsive Disorder Immediate-release oral formulations: Initial dose: 20 mg orally once a day, increased after several weeks if insufficient clinical improvement is observed. Maintenance dose: 20 to 60 mg orally per day Maximum dose: 80 mg orally per day Usual Adult Dose for Panic Disorder Immediate-release oral formulations: Initial dose: 10 mg orally once a day, increased after one week to 20 mg orally once a day Maintenance dose: 20 to 60 mg orally per day Maximum dose: 60 mg orally per day

Route of Administration: Oral

In Vitro Use Guide

Caco-2 SERT was also shown to be a high affinity (Kt=0.216 uM) saturable, Na(+) -dependent transporter that was inhibited by fluoxetine (IC(50)=17.6 nM).

Substance Class	Chemical Created by `admin` on `Fri Dec 16 17:01:05 UTC 2022` Edited by `admin` on `Fri Dec 16 17:01:05 UTC 2022`
Record UNII	I9W7N6B1KJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FLUOXETINE HYDROCHLORIDE

Official Name

English

LY-110140

Code

English

FLUOXETINE HYDROCHLORIDE [JAN]

Common Name

English

PROZAC

Brand Name

English

FONTEX

Brand Name

English

FLUNEURIN

Brand Name

English

LY110140

Code

English

FOXETIN

Brand Name

English

FLUOX-PUREN

Brand Name

English

Fluoxetine hydrochloride [WHO-DD]

Common Name

English

FLUOXETINE HYDROCHLORIDE [USP IMPURITY]

Common Name

English

FLUOXETINE HYDROCHLORIDE [MI]

Common Name

English

FLUOXETINE HYDROCHLORIDE [USAN]

Common Name

English

FLUXET

Brand Name

English

ADOFEN

Brand Name

English

FLUOXETINE HYDROCHLORIDE COMPONENT OF SYMBYAX

Common Name

English

FLUOXETINE HYDROCHLORIDE [HSDB]

Common Name

English

BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)-, HYDROCHLORIDE (1:1)

Systematic Name

English

BENZENEPROPANAMINE, N-METHYL-.GAMMA.-(4-(TRIFLUOROMETHYL)PHENOXY)-, HYDROCHLORIDE, (±)-

Systematic Name

English

FLUOXETINE HYDROCHLORIDE [ORANGE BOOK]

Common Name

English

RECONCILE

Brand Name

English

FLUOXETINE HYDROCHLORIDE [GREEN BOOK]

Common Name

English

SYMBYAX COMPONENT FLUOXETINE HYDROCHLORIDE

Common Name

English

FLUOXETINE HYDROCHLORIDE [USP MONOGRAPH]

Common Name

English

SARAFEM

Brand Name

English

FLUOXETINE HYDROCHLORIDE [USP-RS]

Common Name

English

(±)-N-METHYL-3-PHENYL-3-((.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-P-TOLYL)OXY)PROPYLAMINE, HYDROCHLORIDE

Common Name

English

FLUCTIN

Brand Name

English

LOVAN

Brand Name

English

FLUOXETINE (AS HYDROCHLORIDE)

Common Name

English

FLUSOL

Brand Name

English

FLUOXETINE HYDROCHLORIDE [VANDF]

Common Name

English

FLUOXETINE HYDROCHLORIDE [EP MONOGRAPH]

Common Name

English

FLUOXEREN

Brand Name

English

Classification Tree Code System Code

NCI_THESAURUS

C94725

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

NCI_THESAURUS

C265

Created by admin on Fri Dec 16 17:01:06 UTC 2022 , Edited by admin on Fri Dec 16 17:01:06 UTC 2022

Code System Code Type Description

DAILYMED

I9W7N6B1KJ

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

ECHA (EC/EINECS)

260-101-2

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

CHEBI

5118

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

RXCUI

227224

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

PRIMARY

RxNorm

PUBCHEM

62857

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

PRIMARY

EPA CompTox

DTXSID7020635

Created by admin on Fri Dec 16 17:01:06 UTC 2022 , Edited by admin on Fri Dec 16 17:01:06 UTC 2022

PRIMARY

HSDB

6633

Created by admin on Fri Dec 16 17:01:06 UTC 2022 , Edited by admin on Fri Dec 16 17:01:06 UTC 2022

PRIMARY

RS_ITEM_NUM

1279804

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

PRIMARY

CHEBI

5119

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

EVMPD

SUB02226MIG

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

USAN

AA-47

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

PRIMARY

NCI_THESAURUS

C2829

Created by admin on Fri Dec 16 17:01:07 UTC 2022 , Edited by admin on Fri Dec 16 17:01:07 UTC 2022

PRIMARY

DRUG BANK

DBSALT000087

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

FDA UNII

I9W7N6B1KJ

Created by admin on Fri Dec 16 17:01:06 UTC 2022 , Edited by admin on Fri Dec 16 17:01:06 UTC 2022

PRIMARY

ChEMBL

CHEMBL41

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

MERCK INDEX

M5487

Created by admin on Fri Dec 16 17:01:06 UTC 2022 , Edited by admin on Fri Dec 16 17:01:06 UTC 2022

PRIMARY

Merck Index

CAS

56296-78-7

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

PRIMARY

CAS

59333-67-4

Created by admin on Fri Dec 16 17:01:05 UTC 2022 , Edited by admin on Fri Dec 16 17:01:05 UTC 2022

SUPERSEDED

Related Record Type Details


					01K63SUP8D

FLUOXETINE

PARENT -> SALT/SOLVATE

Related Record Type Details


					G8PMO13PO4

4-TRIFLUOROMETHYLPHENOL

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					I28ND993BO

3-METHYLAMINO-1-PHENYLPROPANOL

IMPURITY -> PARENT

Comments:

This impurity may not be present.

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					PM142C9WRQ

N-METHYL-3-PHENYLPROPAN-1-AMINE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:


					CO7CZX229S

FLUOXETINE SUCCINATE ESTER

IMPURITY -> PARENT


					JWA0C3II9D

N-METHYL-3-PHENYL-3-((ALPHA, ALPHA, ALPHA-TRIFLUORO-M-TOLYL)OXY)PROPYLAMINE HYDROCHLORIDE

IMPURITY -> PARENT

Interaction Type:

CHROMATOGRAPHIC PURITY (HPLC/UV)

Qualification:

USP

Amount:

Related Record Type Details


					01K63SUP8D

FLUOXETINE

ACTIVE MOIETY

Dose	Population	Adverse events
240 mg single, oral Overdose Dose: 240 mg Route: oral Route: single Dose: 240 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 12 - 19 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 12 - 19 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
280 mg single, oral Overdose Dose: 280 mg Route: oral Route: single Dose: 280 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 14 - 19 years n = 3 Health Status: unhealthy Condition: mental disorders Age Group: 14 - 19 years Sex: unknown Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Sleepy, Tremor... AEs leading to discontinuation/dose reduction: Sleepy (1 patient) Tremor (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
260 mg single, oral Overdose Dose: 260 mg Route: oral Route: single Dose: 260 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 15 - 25 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 15 - 25 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Sleepy... AEs leading to discontinuation/dose reduction: Sleepy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 15 - 40 years n = 6 Health Status: unhealthy Condition: mental disorders Age Group: 15 - 40 years Sex: unknown Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Insomnia... AEs leading to discontinuation/dose reduction: Insomnia (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
320 mg single, oral Overdose Dose: 320 mg Route: oral Route: single Dose: 320 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 15 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 15 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
340 mg single, oral Overdose Dose: 340 mg Route: oral Route: single Dose: 340 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 - 22 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 18 - 22 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 1, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
140 mg single, oral Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 - 42 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 18 - 42 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Sleepy... AEs leading to discontinuation/dose reduction: Sleepy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
800 mg single, oral Overdose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 18 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Hypertension... AEs leading to discontinuation/dose reduction: Hypertension (grade 2, 1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 20 - 45 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 20 - 45 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Hypertension, Sleepy... AEs leading to discontinuation/dose reduction: Hypertension (grade 3, 1 patient) Sleepy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
1000 mg single, oral Overdose Dose: 1000 mg Route: oral Route: single Dose: 1000 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 21 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
1500 mg single, oral Overdose Dose: 1500 mg Route: oral Route: single Dose: 1500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 21 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 21 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 28 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 28 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Sore throat... AEs leading to discontinuation/dose reduction: Sore throat (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 29 - 46 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 29 - 46 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Ataxic, Sleepy... AEs leading to discontinuation/dose reduction: Ataxic (1 patient) Sleepy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
400 mg single, oral Overdose Dose: 400 mg Route: oral Route: single Dose: 400 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 31 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 31 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
700 mg single, oral Overdose Dose: 700 mg Route: oral Route: single Dose: 700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 36 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 36 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: GI pain... AEs leading to discontinuation/dose reduction: GI pain (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
120 mg single, oral Overdose Dose: 120 mg Route: oral Route: single Dose: 120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 42 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 42 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
640 mg single, oral Overdose Dose: 640 mg Route: oral Route: single Dose: 640 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 50 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 50 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Sleepy... AEs leading to discontinuation/dose reduction: Sleepy (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
1120 mg single, oral Overdose Dose: 1120 mg Route: oral Route: single Dose: 1120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 51 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 51 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	Disc. AE: Nausea... AEs leading to discontinuation/dose reduction: Nausea (1 patient) Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	Other AEs: Intentional overdose, Suicide attempt... Other AEs: Intentional overdose (serious, 1 patient) Suicide attempt (serious, 1 patient) Suicidal ideation (serious, 1 patient) Faecaloma (serious, 1 patient) Tachycardia (below serious, 5 patients) Vomiting (below serious, 4 patients) Nasopharyngitis (below serious, 7 patients) Decreased appetite (below serious, 10 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	unhealthy, adolescent n = 25 Health Status: unhealthy Condition: Body Dysmorphic Disorder Age Group: adolescent Population Size: 25 Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	Other AEs: Suicidal behavior, Pain stomach... Other AEs: Suicidal behavior (serious, 1 patient) Pain stomach (below serious, 2 patients) Insomnia (below serious, 1 patient) Fatigue (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00245635
544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	Disc. AE: Tachycardia, Drowsiness... AEs leading to discontinuation/dose reduction: Tachycardia (15 patients) Drowsiness (14 patients) Tremor (5 patients) Vomited (4 patients) Nausea (4 patients) Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Other AEs: Asthenia, Vasodilatation... Other AEs: Asthenia (7%) Vasodilatation (1%) Nausea (12%) Diarrhea (9%) Anorexia (5%) Dry mouth (5%) Dyspepsia (6%) Insomnia (10%) Anxiety (6%) Nervousness (8%) Somnolence (5%) Tremor (3%) Libido decreased (1%) Abnormal dreams (1%) Yawn (1%) Sweating (2%) Rash (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
20 mg 1 times / day steady, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 1728 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adult Sex: unknown Population Size: 1728 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Other AEs: Asthenia, Vasodilatation... Other AEs: Asthenia (9%) Vasodilatation (3%) Nausea (21%) Diarrhea (12%) Anorexia (11%) Dry mouth (10%) Dyspepsia (7%) Insomnia (16%) Anxiety (12%) Nervousness (14%) Somnolence (13%) Tremor (10%) Libido decreased (3%) Abnormal dreams (1%) Sweating (8%) Rash (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
20 mg 1 times / day steady, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 266 Health Status: unhealthy Condition: OCD Age Group: adult Sex: unknown Population Size: 266 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Other AEs: Asthenia, Vasodilatation... Other AEs: Asthenia (15%) Vasodilatation (5%) Nausea (26%) Diarrhea (18%) Anorexia (17%) Dry mouth (12%) Dyspepsia (10%) Insomnia (28%) Anxiety (14%) Nervousness (14%) Somnolence (17%) Tremor (9%) Libido decreased (11%) Abnormal dreams (5%) Yawn (7%) Sweating (7%) Rash (6%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
60 mg 1 times / day steady, oral (median) Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/1728831/	unhealthy, adult n = 391 Health Status: unhealthy Condition: obese diabetic Age Group: adult Sex: unknown Population Size: 391 Sources: https://pubmed.ncbi.nlm.nih.gov/1728831/	Other AEs: Headache, Asthenia... Other AEs: Headache (22%) Asthenia (18%) Nausea (18%) Rhinitis (17%) Diarrhoea (15%) Somnolence (13%) Insomnia (12%) Nervousness (10%) Sweating (9%) Flu syndrome (8%) Pain (7%) Anxiety (7%) Dizziness (6%) Tremor (6%) Pharyngitis (5%) Sources: https://pubmed.ncbi.nlm.nih.gov/1728831/
60 mg 1 times / day steady, oral Recommended Dose: 60 mg, 1 times / day Route: oral Route: steady Dose: 60 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 450 Health Status: unhealthy Condition: Bulimia Age Group: adult Sex: unknown Population Size: 450 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Other AEs: Asthenia, Vasodilatation... Other AEs: Asthenia (21%) Vasodilatation (2%) Nausea (29%) Diarrhea (8%) Anorexia (8%) Dry mouth (9%) Dyspepsia (10%) Insomnia (33%) Anxiety (15%) Nervousness (11%) Somnolence (13%) Tremor (13%) Libido decreased (5%) Abnormal dreams (5%) Yawn (11%) Sweating (8%) Rash (4%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, children n = 228 Health Status: unhealthy Condition: mental disorders Age Group: children Sex: unknown Population Size: 228 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	Other AEs: Hypomania... Other AEs: Hypomania (1.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02372799	unhealthy, children\|adolescent n = 97 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: children\|adolescent Population Size: 97 Sources: https://clinicaltrials.gov/ct2/show/NCT02372799	Other AEs: Depressive symptom, Hallucination, auditory... Other AEs: Depressive symptom (serious, 1 patient) Hallucination, auditory (serious, 1 patient) Overdose (serious, 1 patient) Suicidal ideation (serious, 3 patients) Abdominal pain upper (below serious, 4 patients) Upper respiratory tract infection (below serious, 5 patients) Insomnia (below serious, 6 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT02372799
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01372150	unhealthy, children\|adolescents n = 112 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: children\|adolescents Population Size: 112 Sources: https://clinicaltrials.gov/ct2/show/NCT01372150	Other AEs: Suicidal ideation, Suicide attempt... Other AEs: Suicidal ideation (serious, 1 patient) Suicide attempt (serious, 1 patient) Abdominal pain upper (below serious, 9 patients) Nausea (below serious, 13 patients) Vomiting (below serious, 7 patients) Fatigue (below serious, 6 patients) Influenza (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01372150
40 mg 1 times / day steady, oral (max) Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00849901	unhealthy, children\|adolescents n = 117 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: children\|adolescents Population Size: 117 Sources: https://clinicaltrials.gov/ct2/show/NCT00849901	Other AEs: Lymphadenitis, Gastritis... Other AEs: Lymphadenitis (serious, 1 patient) Gastritis (serious, 1 patient) Ulna fracture (serious, 1 patient) Nausea (below serious, 15 patients) Vomiting (below serious, 6 patients) Upper respiratory tract infection (below serious, 3 patients) Incorrect dose administered (below serious, 4 patients) Decreased appetite (below serious, 10 patients) Dizziness (below serious, 4 patients) Headache (below serious, 18 patients) Insomnia (below serious, 6 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT00849901
20 mg single, oral Dose: 20 mg Route: oral Route: single Dose: 20 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	healthy n = 8 Health Status: healthy Sex: M Population Size: 8 Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	Other AEs: Blood triglycerides increased... Other AEs: Blood triglycerides increased (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01569126
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	healthy n = 12 Health Status: healthy Sex: M Population Size: 12 Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	Other AEs: Diarrhoea, Stomatitis... Other AEs: Diarrhoea (below serious, 1 patient) Stomatitis (below serious, 1 patient) Alanine aminotransferase increased (below serious, 2 patients) Aspartate aminotransferase increased (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01569126
20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01635218	unhealthy n = 46 Health Status: unhealthy Condition: Depression Sex: F Population Size: 46 Sources: https://clinicaltrials.gov/ct2/show/NCT01635218	Other AEs: Headache, Anxiety... Other AEs: Headache (below serious, 6 patients) Anxiety (below serious, 8 patients) Dizziness (below serious, 5 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01635218
40 mg single, oral Dose: 40 mg Route: oral Route: single Dose: 40 mg Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	healthy n = 8 Health Status: healthy Sex: M Population Size: 8 Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	Other AEs: White blood cell count decreased... Other AEs: White blood cell count decreased (below serious, 2 patients) Sources: https://clinicaltrials.gov/ct2/show/NCT01569126
40 mg 1 times / day steady, oral Dose: 40 mg, 1 times / day Route: oral Route: steady Dose: 40 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	healthy n = 12 Health Status: healthy Sex: M Population Size: 12 Sources: https://clinicaltrials.gov/ct2/show/NCT01569126	Other AEs: Atrioventricular block first degree, Conjunctivitis allergic... Other AEs: Atrioventricular block first degree (below serious, 2 patients) Conjunctivitis allergic (below serious, 1 patient) Haemorrhoids (below serious, 1 patient) Proctalgia (below serious, 1 patient) Excoriation (below serious, 1 patient) Alanine aminotransferase increased (below serious, 1 patient) Aspartate aminotransferase increased (below serious, 1 patient) Blood triglycerides increased (below serious, 1 patient) White blood cell count decreased (below serious, 1 patient) White blood cell count increased (below serious, 1 patient) Dizziness (below serious, 1 patient) Anxiety (below serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT01569126
80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00288574	unhealthy n = 49 Health Status: unhealthy Condition: Anorexia Nervosa Sex: F Population Size: 49 Sources: https://clinicaltrials.gov/ct2/show/NCT00288574	Other AEs: Suicide attempt... Other AEs: Suicide attempt (serious, 1 patient) Sources: https://clinicaltrials.gov/ct2/show/NCT00288574

AE	Significance	Dose	Population
Sleepy	1 patient Disc. AE	280 mg single, oral Overdose Dose: 280 mg Route: oral Route: single Dose: 280 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 14 - 19 years n = 3 Health Status: unhealthy Condition: mental disorders Age Group: 14 - 19 years Sex: unknown Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Tremor	1 patient Disc. AE	280 mg single, oral Overdose Dose: 280 mg Route: oral Route: single Dose: 280 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 14 - 19 years n = 3 Health Status: unhealthy Condition: mental disorders Age Group: 14 - 19 years Sex: unknown Population Size: 3 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sleepy	1 patient Disc. AE	260 mg single, oral Overdose Dose: 260 mg Route: oral Route: single Dose: 260 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 15 - 25 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 15 - 25 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Insomnia	1 patient Disc. AE	200 mg single, oral Overdose Dose: 200 mg Route: oral Route: single Dose: 200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 15 - 40 years n = 6 Health Status: unhealthy Condition: mental disorders Age Group: 15 - 40 years Sex: unknown Population Size: 6 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Hypertension	grade 1, 1 patient Disc. AE	340 mg single, oral Overdose Dose: 340 mg Route: oral Route: single Dose: 340 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 - 22 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 18 - 22 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sleepy	1 patient Disc. AE	140 mg single, oral Overdose Dose: 140 mg Route: oral Route: single Dose: 140 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 - 42 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 18 - 42 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Hypertension	grade 2, 1 patient Disc. AE	800 mg single, oral Overdose Dose: 800 mg Route: oral Route: single Dose: 800 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 18 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 18 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sleepy	1 patient Disc. AE	600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 20 - 45 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 20 - 45 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Hypertension	grade 3, 1 patient Disc. AE	600 mg single, oral Overdose Dose: 600 mg Route: oral Route: single Dose: 600 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 20 - 45 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 20 - 45 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sore throat	1 patient Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 28 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 28 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Ataxic	1 patient Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 29 - 46 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 29 - 46 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sleepy	1 patient Disc. AE	1200 mg single, oral Overdose Dose: 1200 mg Route: oral Route: single Dose: 1200 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 29 - 46 years n = 2 Health Status: unhealthy Condition: mental disorders Age Group: 29 - 46 years Sex: unknown Population Size: 2 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
GI pain	1 patient Disc. AE	700 mg single, oral Overdose Dose: 700 mg Route: oral Route: single Dose: 700 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 36 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 36 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Sleepy	1 patient Disc. AE	640 mg single, oral Overdose Dose: 640 mg Route: oral Route: single Dose: 640 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 50 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 50 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Nausea	1 patient Disc. AE	1120 mg single, oral Overdose Dose: 1120 mg Route: oral Route: single Dose: 1120 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/	unhealthy, 51 years n = 1 Health Status: unhealthy Condition: mental disorders Age Group: 51 years Sex: unknown Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/2231832/
Decreased appetite	below serious, 10 patients	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Vomiting	below serious, 4 patients	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Tachycardia	below serious, 5 patients	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Nasopharyngitis	below serious, 7 patients	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Faecaloma	serious, 1 patient	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Intentional overdose	serious, 1 patient	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Suicidal ideation	serious, 1 patient	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Suicide attempt	serious, 1 patient	20 mg 1 times / day steady, oral Dose: 20 mg, 1 times / day Route: oral Route: steady Dose: 20 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT02431806	unhealthy, adolescent n = 134 Health Status: unhealthy Condition: Major Depressive Disorder Age Group: adolescent Population Size: 134 Sources: https://clinicaltrials.gov/ct2/show/NCT02431806
Fatigue	below serious, 1 patient	80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	unhealthy, adolescent n = 25 Health Status: unhealthy Condition: Body Dysmorphic Disorder Age Group: adolescent Population Size: 25 Sources: https://clinicaltrials.gov/ct2/show/NCT00245635
Insomnia	below serious, 1 patient	80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	unhealthy, adolescent n = 25 Health Status: unhealthy Condition: Body Dysmorphic Disorder Age Group: adolescent Population Size: 25 Sources: https://clinicaltrials.gov/ct2/show/NCT00245635
Pain stomach	below serious, 2 patients	80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	unhealthy, adolescent n = 25 Health Status: unhealthy Condition: Body Dysmorphic Disorder Age Group: adolescent Population Size: 25 Sources: https://clinicaltrials.gov/ct2/show/NCT00245635
Suicidal behavior	serious, 1 patient	80 mg 1 times / day steady, oral (max) Dose: 80 mg, 1 times / day Route: oral Route: steady Dose: 80 mg, 1 times / day Sources: https://clinicaltrials.gov/ct2/show/NCT00245635	unhealthy, adolescent n = 25 Health Status: unhealthy Condition: Body Dysmorphic Disorder Age Group: adolescent Population Size: 25 Sources: https://clinicaltrials.gov/ct2/show/NCT00245635
Drowsiness	14 patients Disc. AE	544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
Tachycardia	15 patients Disc. AE	544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
Nausea	4 patients Disc. AE	544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
Vomited	4 patients Disc. AE	544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
Tremor	5 patients Disc. AE	544 mg single, oral (mean) Overdose Dose: 544 mg Route: oral Route: single Dose: 544 mg Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/	unhealthy, adult n = 37 Health Status: unhealthy Condition: mental disorders Age Group: adult Sex: unknown Population Size: 37 Sources: https://pubmed.ncbi.nlm.nih.gov/1586402/
Abnormal dreams	1%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Libido decreased	1%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Vasodilatation	1%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Yawn	1%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Insomnia	10%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Nausea	12%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Rash	2%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf
Sweating	2%	10 mg 1 times / day steady, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: steady Dose: 10 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf	unhealthy, adult n = 425 Health Status: unhealthy Condition: Panic Disorder Age Group: adult Sex: unknown Population Size: 425 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018936s108lbl.pdf

Details

SMILES

InChI

DescriptionSources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf | https://www.drugs.com/fluoxetine.html

CNS Activity

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Approved Use

Launch Date

Cmax

AUC

T1/2

Funbound

Doses

AEs

Overview

OverviewOther

Drug as perpetrator​

Drug as victim

Tox targets

Sourcing

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018936s091lbl.pdf | https://www.drugs.com/fluoxetine.html

C_max

T_1/2

F_unbound

Drug as perpetrator